BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX)
Health Care · Biotechnology · US
$8.29
-1.31% today · +13.9% 1Y
BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.12B and employs 435 people.
Over the last twelve months the share price has gained 13.9%, trading between 6.00 and 11.22.
Tweenvest scores BioCryst Pharmaceuticals, Inc. across four factors: quality 44/100, value 57/100, growth 100/100. Its strongest factor is growth.
BCRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.12B
- Revenue (TTM)
- $940.61M
- P/E
- —
- EPS
- -1.68
- Dividend yield
- —
- Beta (5Y)
- 0.55
- 52-week high
- $11.22
- 52-week low
- $6.00
- Avg volume (3M)
- —
- Shares outstanding
- 255.54M
- Employees
- 435
- Next earnings
- —
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
- ISIN
- US09058V1035
- Founded
- 1986
- Listed since
- Mar 4, 1994
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Vera Therapeutics, Inc.NasdaqGM: VERA | $2.19B | $29.73 | -2.27% |
| Aurinia Pharmaceuticals Inc.NasdaqGM: AUPH | $2.16B | $16.22 | +1.31% |
| ABL Bio Inc.KOSDAQ: A298380 | $2.14B | ₩51,400.00 | +1.18% |
| Wuhan Healthgen Biotechnology Corp.SHSE: 688765 | $2.12B | CN¥39.84 | -2.95% |
| Recursion Pharmaceuticals, Inc.NasdaqGS: RXRX | $2.12B | $3.95 | -7.49% |
| SK bioscience Co.,Ltd.KOSE: A302440 | $2.12B | ₩36,500.00 | +2.10% |
| Nanjing Vazyme Biotech Co., LtdSHSE: 688105 | $2.10B | CN¥27.24 | +2.52% |
| Mineralys Therapeutics, Inc.NasdaqGS: MLYS | $2.09B | $22.38 | -5.29% |
Figures last refreshed Oct 4, 2026.